Genetic screening of compounds used in drug abuse treatment. III. LAAM.
Several compounds used clinically in drug abuse therapy were evaluated for genetic activity in a series of in vivo and in vitro assays. This third report in the series describes the results for one of these compounds, LAAM (L-alpha-acetyl methadol). Previous reports described results from a three phase testing program for Naltrexone and Methadone. LAAM is related chemically to the narcotic analgesic oxymorphine, and is related chemically to a narcotic antagonist, naloxone. LAAM exhibited genetic activity in the ad-3 forward-mutation test in Neurospora crassa and also was weakly mutagenic in the mouse lymphoma forward-mutation assay. Further analysis of the ad-3 mutants from N. crassa indicated that they were the result of a parasexual phenomenon rather than forward mutation. There was one confirmed translocation carrier in the heritable translocation study, which by conservative interpretation might imply some germ-cell risk associated with exposure to LAAM.
D000818:Animals; D001854:Bone Marrow Cells; D004260:DNA Repair / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D008223:Lymphoma / Q000235:genetics; D008691:Methadone / Q000031:analogs & derivatives*; D008692:Methadyl Acetate / Q000633:toxicity*; D051379:Mice; D009153:Mutagens; D009374:Neoplasms, Experimental / Q000235:genetics; D009492:Neurospora crassa / Q000187:drug effects; D012486:Salmonella typhimurium / Q000235:genetics; D019966:Substance-Related Disorders / Q000188:drug therapy
D009153:Mutagens; D008692:Methadyl Acetate; D008691:Methadone